ARCTICZYMES TECHNOLOGIES ASA
Sector unknown·AZT · Oslo Børs·Fiscal year to 31/12/2024
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Biotech and drug development
Technology
DriverPositive impact: strengthens
“Molecular Research and MDx represent highly attractive and growing markets with estimated end-user market values of USD 23.2—30.4 billion (CAGR 5.4%).”
Annual report 2024A · The company itself
Market
“At the forefront of the industry are fast-paced innovations around Next Generation Sequencing (NGS) technologies with the prospect of wider adoption, accessibility, and clinical utility. All ArcticZymes´ existing enzymes, as well as its pipeline innovations, are available for this application and represent integral key components for adoption into NGS technologies by leading international companies. Furthermore, ArcticZymes’ ability to customize and tailor enzymes is becoming a more important value driver for NGS platform developers.”
Annual report 2024A · The company itself
Market
“ArcticZymes sales revenues are from sales of enzymes for use in molecular research, In Vitro Diagnostics and Biomanufacturing.”
Annual report 2024A · The company itself
Market
“ArcticZymes is supplying SAN products directly to more than 223 customers. In addition, ArcticZymes supplies SAN products to further customers via distributors. Most customers are gene therapy-related and represent a mix of small/medium biotech companies, contract development manufacturing organizations (CDMOs), and large Pharma.”
Annual report 2024A · The company itself
Market
“Board of Directors’ Report 2024 9 A notable trend in the CGT (Cell and Gene Therapy) space is a growing focus on the Contract Development and Manufacturing Organization (CDMO) model. This shift contrasts sharply with the landscape 5–10 years ago, when many biotech companies were heavily focused on building in- house manufacturing capabilities. Consequently, for ArcticZymes, integrating our nuclease products into CDMO platforms has become increasingly vital for short term revenue and also long-term growth and market presence.”
Annual report 2024A · The company itself
Chains in: US drug pricing policy mixed effect, Patent expiry and generic competition weakens, Drug approvals strengthens
Chains out: this strengthens Buying contract manufacturing and research (CMO/CRO/EMS), strengthens Contract manufacturers as a business (EMS, CMO, CRO)
Enzymes and biosolutions
Technology
StrategyPositive impact: strengthens
“Innovation remains a cornerstone of our strategy. The ADEPT project is driving the development of our first mRNA enzymes, and we will continue to expand our molecular tools offerings with new amplification and sample preparation solutions.”
Annual report 2024A · The company itself
Market
“ArcticZymes AS Product Offering ArcticZymes enzymes are primarily derived from cold-water marine species and organisms from other environments. Each enzyme or product offers novel functionality and other benefits to its customers. Products offered include: utilisation in clean-up prior to Sanger sequencing and NGS (Next Generation Sequencing) processes.”
Annual report 2024A · The company itself
Market
“Shrimp Alkaline Phosphatase (SAP) – For The Company is creating value from innovative enzyme technologies which capitalises on more than three decades of world-class research at the Arctic University of Tromsø and collaborations with national and international partners to offer niche and highquality life science products. utilised for enzymatic clean-up in Sanger Sequencing processes globally. ArcticZymes Technologies’ products and capabilities are protected via a large portfolio of patents and 20+ years of know-how in innovating and manufacturing enzymes. contaminating dU-DNA providing assurance to avoid false positives tests.”
Annual report 2024A · The company itself
Market
“Board of Directors’ Report 2024 8 Other technology areas ArcticZymes serves through its enzymes include: • Synthetic Biology - a multidisciplinary area engaged in creating new biological parts, devices, systems relying on a plethora of molecular biology techniques. ArcticZymes’ ligase prototypes, polymerases, and pipeline innovations, including DNA assembly, show great promise for future utility in this market. • Liquid Biopsies – DNA or other diagnostics tests are performed on blood or other body fluids.”
Annual report 2024A · The company itself
Market
“The Company received a 12 MNOK grant from the Research council of Norway to develop new innovative mRNA enzymes. A consortium has been established together with SINTEF and the University of Tromsø with the aim of developing new enzymatic technologies that can aid the manufacturing of mRNA based therapeutics. The project runs over three years and 2.5 MNOK was expensed on this project in 2024.”
Annual report 2024A · The company itself
Vaccines (travel health and preparedness)
End markets
Market
“Our Salt Active Nuclease (SAN) program remained a key priority. We made strong progress toward launching a comprehensive GMP-grade nuclease portfolio by mid- 2025. This will uniquely position ArcticZymes to support gene therapies—AAV and Lentivirus—as well as broader biologics like viral vaccines.”
Annual report 2024A · The company itself
Market
“Biomanufacturing ArcticZymes is serving customers with Salt Active Nuclease (SAN) products who are in different stages of therapeutic or vaccine development. The SAN portfolio of enzymes is used for removing non-encapsulated nucleic acid impurities from therapeutic viruses such as Adenovirus, Adeno-Associated Virus (AAV), and Lentivirus. This reduces the risk of adverse effects in the final vaccine product.”
Annual report 2024A · The company itself
Market
“In 2024, ArcticZymes has continued to prioritize organic growth initiatives, making significant strides in its SAN (Salt Active Nuclease) program to achieve a comprehensive GMP nuclease portfolio. • Cell biology/Cell therapy: proteolytic enzymes such as ArcticZymes’ Proteinase represent essential tools for the dissociation and isolation of cells from patients for ex vivo manipulation and treatment. • RNA Therapeutics: The Coronavirus pandemic demonstrated the commercial utility and acceptance of mRNA technology as a therapeutic tool in rapid vaccine manufacturing effective and safe RNA-based vaccines. mRNA technology represents a powerful technology that can be extended to the development of other vaccines or gene therapy applications. Unlike viral vector manufacturing, multiple enzymes are required to manufacture therapeutic mRNAs where the need for novel and high-quality enzymes is in high demand.”
Annual report 2024A · The company itself
Market
“The Company received a 12 MNOK grant from the Research council of Norway to develop new innovative mRNA enzymes. A consortium has been established together with SINTEF and the University of Tromsø with the aim of developing new enzymatic technologies that can aid the manufacturing of mRNA based therapeutics. The project runs over three years and 2.5 MNOK was expensed on this project in 2024.”
Annual report 2024A · The company itself
Market
“Furthermore, a new patented RNA restriction enzyme (ET-N1 is under development and is expected to be the Company’s first unique enzyme offering within the RNA space. Sales in the Biomanufacturing segment experienced a 14% annual decline (-7.7 MNOK) and contributed 47% toward total sales during 2024.”
Annual report 2024A · The company itself
Chains in: Pandemics and outbreaks strengthens
Gene and cell therapy
Technology
StrategyPositive impact: strengthens
“The focus on becoming an attractive partner within biomanufacturing has demanded investments in the establishment of a DMF (Drug Master File) as well as a GMP upgrades for the Company’s SAN portfolio. By H2 2025, the Company will be uniquely positioned as provider of specialized GMP and non-GMP enzymes optimized for the two major classes of gene therapies—AAV and Lenti-virus. These enzymes will also support other biologics, such as viral vaccines, establishing a critical foundation for revenue growth in 2025 and beyond.”
Annual report 2024A · The company itself
Market
“Our Salt Active Nuclease (SAN) program remained a key priority. We made strong progress toward launching a comprehensive GMP-grade nuclease portfolio by mid- 2025. This will uniquely position ArcticZymes to support gene therapies—AAV and Lentivirus—as well as broader biologics like viral vaccines.”
Annual report 2024A · The company itself
Market
“Biomanufacturing ArcticZymes is serving customers with Salt Active Nuclease (SAN) products who are in different stages of therapeutic or vaccine development. The SAN portfolio of enzymes is used for removing non-encapsulated nucleic acid impurities from therapeutic viruses such as Adenovirus, Adeno-Associated Virus (AAV), and Lentivirus. This reduces the risk of adverse effects in the final vaccine product.”
Annual report 2024A · The company itself
Market
“In 2024, ArcticZymes has continued to prioritize organic growth initiatives, making significant strides in its SAN (Salt Active Nuclease) program to achieve a comprehensive GMP nuclease portfolio. • Cell biology/Cell therapy: proteolytic enzymes such as ArcticZymes’ Proteinase represent essential tools for the dissociation and isolation of cells from patients for ex vivo manipulation and treatment. • RNA Therapeutics: The Coronavirus pandemic demonstrated the commercial utility and acceptance of mRNA technology as a therapeutic tool in rapid vaccine manufacturing effective and safe RNA-based vaccines. mRNA technology represents a powerful technology that can be extended to the development of other vaccines or gene therapy applications. Unlike viral vector manufacturing, multiple enzymes are required to manufacture therapeutic mRNAs where the need for novel and high-quality enzymes is in high demand.”
Annual report 2024A · The company itself
Medical devices
Technology
Market
“ArcticZymes’ ligase prototypes, polymerases, and pipeline innovations, including DNA assembly, show great promise for future utility in this market. • Liquid Biopsies – DNA or other diagnostics tests are performed on blood or other body fluids. The market is growing (CAGR 11.9%) with an estimated market size of USD 6.4 Billion. Unlike traditional invasive biopsies, liquid biopsies require a whole new set of molecular techniques to overcome the challenges of isolating tiny amounts of DNA and amplifying it sufficiently to allow diagnostic insights to be derived.”
Annual report 2024A · The company itself
Market
“ArcticZymes sales revenues are from sales of enzymes for use in molecular research, In Vitro Diagnostics and Biomanufacturing.”
Annual report 2024A · The company itself
Chains in: Ageing population strengthens
Artificial intelligence
Technology
StrategyPositive impact: strengthens
“The Company has also initiated projects with partners where AI is applied to speed up development of new novel enzymes. Markets Served The Company focuses its efforts on providing molecular biology enzymes in two attractive and growing market areas: • Molecular Tools (Research & Diagnostics) • Biomanufacturing Molecular Tools Molecular enzymes are essential tools that are used in molecular biology workflows to perform specific tasks.”
Annual report 2024A · The company itself
Chains out: this strengthens Data centres, strengthens Semiconductors and electronic components, strengthens Semiconductor industry
Shipping and logistics
End markets
DriverPositive impact: strengthens
“To support sales activities, ArcticZymes has established strategically located warehouses and logistic centres in Europe and the United States. These centres have made it possible to build inventories and safety stocks, improve the cost- effectiveness of logistics, and most importantly, ensure on-demand delivery to customers on a global basis.”
Annual report 2024A · The company itself
Chains in: Carbon tax and ETS prices weakens, Global trade volumes strengthens, Fuel strengthens
Asia and emerging markets
Geography
Geography
“Geographically, Europe represented the largest market with 71% of total sales while North America contributed about 26% and Asia Pacific about 2.7%.”
Annual report 2024A · The company itself
Geography
“The Asia Pacific region was the only geographical area exhibiting sales growth on an annual basis (+33%) and constituted the majority of the remaining sales for this segment. India (3.8% of total sales) and China (3.7% of total sales) were the main contributors from the APAC region.”
Annual report 2024A · The company itself
Geography
“As ArcticZymes is a global supplier of enzymes, most of the sales and marketing team are located remotely in Central Europe, North-America and Japan.”
Annual report 2024A · The company itself
Geography
“ArcticZymes has local business development and customer support representatives in Europe, North America, Japan, and China to assist with global business coverage.”
Annual report 2024A · The company itself
Europe
Geography
Geography
“Geographically, Europe represented the largest market with 71% of total sales while North America contributed about 26% and Asia Pacific about 2.7%.”
Annual report 2024A · The company itself
Geography
“Geographically, North America represented the largest market with close to 64% of total sales while Europe contributed about 28%.”
Annual report 2024A · The company itself
Geography
“As ArcticZymes is a global supplier of enzymes, most of the sales and marketing team are located remotely in Central Europe, North-America and Japan.”
Annual report 2024A · The company itself
Geography
“Much of the annual growth in sales is through a combination of: • Improving sales coverage in key markets. • Entering the market for GMP-compliant products. • Increasing the customer base. • Expanding the product range with market-driven, innovative product introductions. • Serving two attractive and growing markets: molecular tools and biomanufacturing. • Expanding geographical reach through partnerships. ArcticZymes has local business development and customer support representatives in Europe, North America, Japan, and China to assist with global business coverage.”
Annual report 2024A · The company itself
United States
Geography
Geography
“Geographically, Europe represented the largest market with 71% of total sales while North America contributed about 26% and Asia Pacific about 2.7%.”
Annual report 2024A · The company itself
Geography
“Slowdown from two major accounts represented significant headwinds in 2024, which were partially offset by sales growth in other accounts as well as growth in the overall customer base. Geographically, North America represented the largest market with close to 64% of total sales while Europe contributed about 28%.”
Annual report 2024A · The company itself
Geography
“As ArcticZymes is a global supplier of enzymes, most of the sales and marketing team are located remotely in Central Europe, North-America and Japan.”
Annual report 2024A · The company itself
Geography
“Much of the annual growth in sales is through a combination of: • Improving sales coverage in key markets. • Entering the market for GMP-compliant products. • Increasing the customer base. • Expanding the product range with market-driven, innovative product introductions. • Serving two attractive and growing markets: molecular tools and biomanufacturing. • Expanding geographical reach through partnerships. ArcticZymes has local business development and customer support representatives in Europe, North America, Japan, and China to assist with global business coverage.”
Annual report 2024A · The company itself
Chains in: USD vs DKK/EUR mixed effect
Geopolitical uncertainty
Macro
DriverNegative impact: weakens
“Board of Directors’ Report 2024 12 The war in Ukraine, Middle Eastern instability, and trade tensions The ongoing war in Ukraine, along with instability in the Middle East, has not had a direct material impact on the Company. ArcticZymes has no existing or potential business in these regions. However, these conflicts contribute to broader economic uncertainty, which may indirectly affect the Company by dampening the global investment climate and slowing overall economic growth.”
Annual report 2024A · The company itself
Chains out: this strengthens Defence budgets, strengthens Energy security, strengthens Tariffs and trade policy, weakens Global trade volumes, strengthens Sea freight and freight rates, weakens Reconstruction of Ukraine
Tariffs and trade policy
Macro
DriverNegative impact: weakens
“Additionally, escalating trade tensions and protectionist policies in key markets have led to a more fragmented global trade environment. While ArcticZymes is not directly impacted currently, disruptions to global supply chains and shifting international trade dynamics create further economic uncertainty that could influence the broader business landscape.”
Annual report 2024A · The company itself
Chains in: Geopolitical uncertainty strengthens
Chains out: this weakens Global trade volumes
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 0.1 bn NOK |
| Revenue growth vs. the year before, same method | -12.3 % |
| EBITDA reported by the company | 0.01 bn NOK |
| Net debt debt incl. leasing minus cash | N/A |
| Diluted EPS per share | 0.17 NOK |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | ✓ |
| Growing | ✗ |
| Healthy balance sheet | N/A |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (NOK), not converted to DKK. Quotes are shown as the company's own words in the report's original language.